Suchergebnisse - "Hanley, Michael J"

PubPharm (13)

1

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients

enthalten in: CPT: pharmacometrics & systems pharmacology | 2022

von Srimani, J. | Diderichsen, P. | Hanley, M. | +3

2

Clinical Pharmacology of Ixazomib : The First Oral Proteasome Inhibitor

enthalten in: Clinical pharmacokinetics | 2019

von Gupta, N. | Hanley, M. | Xia, C. | +3

3

Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

enthalten in: Clinical pharmacology and therapeutics | 2019

von Gupta, N. | Hanley, M. | Diderichsen, P. | +9

4

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2018

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

5

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor : Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

enthalten in: Journal of clinical pharmacology | 2018

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +13

6

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2018

von Hanley, M. | Gupta, N. | Venkatakrishnan, K. | +6

7

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

enthalten in: Clinical pharmacokinetics | 2017

von Gupta, N. | Diderichsen, P. | Hanley, M. | +4

8

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma : Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6

9

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma : China Continuation study

enthalten in: Journal of hematology & oncology | 2017

von Hou, J. | Jin, J. | Xu, Y. | +18

10

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2016

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +5